Core Viewpoint - He Eye Hospital (301103) has seen a significant increase in financing activities, with a net financing purchase of 128.21 million yuan on December 5, 2025, indicating strong investor interest and confidence in the stock [1][2]. Financing Activities Summary - On December 5, 2025, the financing buy-in amounted to 437.04 million yuan, while financing repayment was 308.83 million yuan, resulting in a net financing purchase of 128.21 million yuan [1]. - The financing balance reached 6864.65 million yuan, with a net financing purchase of 382.06 million yuan over the last three trading days [1]. - In the past 20 trading days, there were 14 days with net financing purchases, reflecting consistent demand for the stock [1]. Daily Financing Data - On December 5, 2025, the net financing purchase was 128.21 million yuan, with a financing balance of 6864.65 million yuan, representing 2.17% of the circulating market value [2]. - The financing balance has shown a steady increase, with a rise of 1.9% on December 5 compared to the previous day [3]. - The financing balance has increased from 6301.00 million yuan on December 1 to 6864.65 million yuan on December 5, indicating a positive trend in investor engagement [2][3].

《蓝皮书》正式发布。(联盟供图) 据悉，上海市眼病防治中心已于全市16个区开展AI赋能社区居民视觉健康管理试点工作，并与江苏省 东台市、浙江省台州市等建立合作，在长三角地区促进和推动构建同质化、一体化的视觉健康服务体 系。 《蓝皮书》历时两年编撰，汇聚30余位跨学科专家智慧，由复旦大学出版社出版。作为聚焦视觉健康数 智化转型的专项成果，其首次系统阐述了视觉健康领域数智化转型的核心逻辑，以长三角实践为样本形 成可借鉴、可推广的来自长三角的方案，为中国乃至全球视觉健康事业发展提供参考。 中新网上海12月7日电 (记者 陈静)记者7日获悉，在刚刚结束的长三角眼病防治专科联盟(简称：联 盟)2025年度总结会(简称：总结会)上，《长三角视觉健康数智化转型蓝皮书》(以下简称《蓝皮书》)正 式发布。 《蓝皮书》的创新在于首次提出了视觉健康数智化的概念，并构建了视觉健康数智化成熟度评估架构， 填补了行业在数智化转型评估领域的空白，为区域视觉健康数智化转型提供了明确的评价标准，有助于 精准定位转型过程中的短板与改进方向。为推动理论落地，专家团队还将大数据、5G、人工智能、大 模型、机器人、云服务等前沿技术，拆解为自动化眼病筛 ...

Group 1 - The company announced the resignation of its General Manager, He Wei, who will focus on his role as Chairman to enhance the company's governance structure and decision-making efficiency [2][3] - He Wei remains a significant shareholder, holding 30,327,379 shares directly and 5,146,921 shares indirectly, and will continue to serve as Chairman and on various committees [3] - The company appointed He Xingru as the new General Manager, effective from the date of the board's approval, to oversee daily operations [4][13] Group 2 - The company held its 14th meeting of the third board on December 5, 2025, where it approved the first grant of restricted stock under the 2025 incentive plan, awarding 5.1 million shares to 240 eligible participants at a price of 13.00 yuan per share [10][17] - The incentive plan aims to enhance employee cohesion and operational efficiency, with performance targets set for the years 2025 to 2027 [23][35] - The plan includes specific conditions for stock vesting, which are tied to the company's performance metrics and individual assessments [24][36]

Group 1 - The sixth Dreamer Charity Conference was held in Beijing, where Aier Eye Hospital was awarded the "Annual Charity Contribution" award for its outstanding contributions to the public welfare sector [1][5] - Aier Eye Hospital has integrated social responsibility into its development strategy over the past two decades, combining "blood transfusion" and "blood production" to support rural revitalization and care for vulnerable groups [2] - The hospital has established a comprehensive eye health assistance system targeting various diseases, providing precise aid to disadvantaged patients, including the elderly, children, women, and the disabled [2] Group 2 - Under the national rural revitalization strategy, Aier Eye Hospital aims to achieve equalization of urban and rural medical services, establishing a three-tier eye health public health service system [3] - The hospital has implemented innovative digital technologies, such as equipping township health centers with AI fundus cameras, enhancing the diagnostic capabilities of grassroots medical institutions [3] - Aier Eye Hospital has supported a total of 873 public welfare projects across over 300 regions in 31 provinces, autonomous regions, and municipalities, and has won the "China Charity Award" for three consecutive years [4] Group 3 - In the future, Aier Eye Hospital plans to deepen its sustainable public welfare model, contributing to the construction of a healthy China [6]

Core Insights - He Eye Hospital Group has been awarded the "2025 Listed Company ESG Value Transmission Award" and the "2025 Listed Company AI Frontier Innovation Award" at the recent China AI Track and ESG Sustainable Development Conference, recognizing its efforts in ESG value transmission and AI applications in ophthalmology [1][3] Group 1: ESG and Social Responsibility - He Eye Hospital has actively fulfilled its social responsibilities and practiced sustainable development by building a human-centered eye health system through advocacy, capacity building, treatment rehabilitation, charity, and public education [2] - The hospital has trained over 50,000 grassroots doctors and eye health management personnel as a training base for the National Health Commission's blindness prevention and treatment initiatives [2] Group 2: Technological Innovation and Strategy - Under the "Technology Empowering Eye Health" strategy, He Eye Hospital aims to reduce costs, increase efficiency, and expand boundaries by deeply integrating digital transformation with AI technology [2] - The hospital has established an intelligent system covering the entire medical chain, focusing on four core goals: data asset accumulation, service experience enhancement, medical efficiency breakthroughs, and ecological collaboration deepening [2] Group 3: Future Focus and International Cooperation - The company plans to continue focusing on gene therapy, stem cell medicine, and smart healthcare, promoting the deep integration of new technologies like AI with clinical needs [3] - He Eye Hospital aims to enhance its international cooperation and public welfare practices to convey ESG values in the field of eye health [3]

Core Points - He Eye Hospital announced the resignation of its General Manager, He Wei, who will continue to serve as the Chairman of the Board and other committee roles [1] - The Board of Directors has appointed He Xingru as the new General Manager, responsible for daily operations [1] Company Changes - He Wei's resignation is part of a strategy to enhance decentralization and ensure the company's independence [1] - He Xingru's appointment as General Manager is effective immediately following the Board's approval and will last until the current Board's term ends [1]

Core Insights - He Eye Hospital has been awarded the "2025 Annual Listed Company ESG Value Transmission Award" and the "2025 Annual Listed Company AI Frontier Innovation Award" for its continuous efforts in ESG value transmission and pioneering applications of artificial intelligence in ophthalmology [1] Group 1: ESG Commitment - He Eye Hospital has been dedicated to the field of eye health for 30 years, focusing on prevention and treatment, and providing specialized ophthalmic diagnosis and vision care services [2] - As of June 30, 2025, the company operates 127 ophthalmic service institutions across key regions in China, aligning with the "Healthy China" strategy and the United Nations Sustainable Development Goals [2] - The company has trained over 50,000 grassroots doctors and eye health management personnel, contributing to a people-centered eye health system [2] Group 2: AI Innovations - The recognition of the AI Frontier Innovation Award highlights He Eye Hospital's technological innovation and clinical implementation capabilities in smart healthcare [3] - The company has integrated AI technology into its operations, enhancing efficiency in data collection and analysis, and optimizing clinical services through an AI imaging cloud platform [3] - The "He Diabetes Manager" utilizes AI deep learning algorithms for real-time blood sugar monitoring, aiming for precise diabetes management and eye disease prevention [3] Group 3: Refractive Surgery Advancements - In the field of refractive surgery, AI technology is applied to create personalized models for corneal aberration data, shifting surgical decision-making from experience-based to data-driven [4] - AI technology aids in preoperative risk assessment by intelligently analyzing eye images, enhancing surgical safety and control [4] - The integration of AI with visualization systems allows for better patient experience by presenting postoperative outcomes and optimizing surgical processes [4]

Core Viewpoint - The company announces a leadership change, with the current General Manager resigning due to governance and business development needs, while remaining as Chairman [1] Group 1 - The Chairman and General Manager, He Wei, has applied for resignation from the General Manager position [1] - He Wei will continue to serve as the Chairman of the company after his resignation [1] - The board of directors has approved the appointment of He Xingru as the new General Manager, effective from the date of the board's approval until the end of the third board's term [1]

Core Insights - The collaboration between Tongji University Affiliated Tongji Hospital and Guangzheng Ophthalmology has led to the development of innovative glaucoma drainage valves and anterior chamber puncture devices, winning multiple awards at national competitions [1][2] Group 1: Awards and Recognition - The glaucoma treatment patent won first prize and third prize at the 2025 China Medical Device Innovation and Entrepreneurship Competition, and second prize at the 2025 Yangtze River Delta Industrial Innovation Patent Operation Competition [1] - The awarded patents are now entering subsequent research trials and clinical application phases, supported by collaborations and financing from several well-known medical technology companies [2] Group 2: Collaborative Innovation - Guangzheng Ophthalmology has established three major innovation platforms in collaboration with top institutions, focusing on AI ophthalmic diagnostic systems and minimally invasive treatment device development [3] - The recent patent breakthrough in glaucoma treatment reflects the success of Guangzheng Ophthalmology's innovation research system, emphasizing its commitment to driving advancements in ophthalmic medical technology [3] Group 3: Future Directions - Guangzheng Ophthalmology plans to leverage the recent awards to deepen its focus on the "AI + healthcare" sector, enhancing partnerships with academic and research institutions [3] - The company aims to increase investment in cutting-edge fields such as AI diagnosis and gene therapy, integrating innovative results into its medical service network for broader patient benefit [3]

Group 1 - The company, Chaoyue Eye Care (02219.HK), announced a share buyback on December 4, spending HKD 320,000 to repurchase 120,000 shares at a price range of HKD 2.63 to 2.70 per share [1]